May - 2014
| Previous Next | Showing Journal 5 of 15 |
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosisthe ASCEND Study Group N Eng J Med, 2014, May 18, 2014DOI: 10.1056/NEJMoa1402582 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
May |
Previous Comments
No Comments yet.
Comment
This 1 of 3 articles published in the NEJM this week reporting outcomes of new interventions for idiopathic pulmonary fibrosis (IPF). Pirfenidone is an oral antifibrotic agent, with some previous trials suggesting a reduction in decline in FVC in IPF. The equivocal nature of the data led the US...